Suppr超能文献

钠-葡萄糖协同转运蛋白2抑制剂与肾脏:作用及机制

SGLT2 inhibitors and the kidney: Effects and mechanisms.

作者信息

Tsimihodimos V, Filippatos T D, Elisaf M S

机构信息

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.

Department of Internal Medicine, School of Medicine, University of Crete, Crete, Greece.

出版信息

Diabetes Metab Syndr. 2018 Nov;12(6):1117-1123. doi: 10.1016/j.dsx.2018.06.003. Epub 2018 Jun 6.

Abstract

AIMS

Numerous clinical trials have shown that sodium glucose cotransporter 2 (SGLT2) inhibitors exert a favorable effect on the indices of renal function (albuminuria, glomerular filtration rate decline over time) and the incidence of hard renal endpoints such as renal death or time to initiation of renal replacement therapy.

MATERIALS AND METHODS

In this review, we describe in detail the evidence regarding the nephroprotective mechanisms of SGLT2 inhibitors and describe the risk factors that may predispose to the development of acute kidney injury in patients receiving these drugs.

RESULTS

Although the impact of these drugs on renal hemodynamics seems to represent the most important renoprotective mechanism of action, many other effects of these compounds, including beneficial effects on metabolism and blood pressure, have been proposed to contribute to the observed clinical benefit.

CONCLUSIONS

SGLT2 inhibitors clearly act beneficially in terms of kidney function with many proposed mechanisms.

摘要

目的

众多临床试验表明,钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂对肾功能指标(蛋白尿、肾小球滤过率随时间下降)以及严重肾脏终点事件(如肾脏死亡或开始肾脏替代治疗的时间)的发生率具有有益影响。

材料与方法

在本综述中,我们详细描述了关于SGLT2抑制剂肾脏保护机制的证据,并描述了接受这些药物治疗的患者可能易发生急性肾损伤的危险因素。

结果

尽管这些药物对肾脏血流动力学的影响似乎是最重要的肾脏保护作用机制,但这些化合物的许多其他作用,包括对代谢和血压的有益作用,也被认为有助于观察到的临床获益。

结论

SGLT2抑制剂通过多种提出的机制,在肾功能方面显然发挥着有益作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验